Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE — Stella

Home/Systemic Lupus Erythematosus/

View on ClinicalTrials.gov

Recruiting

Back to Systemic Lupus Erythematosus trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu

Key details

Phase

Early testing

Sponsor

Chongqing Precision Biotech Co., Ltd

Enrollment target

~18 participants

Started

January 2026

Primary completion

July 2026

Age range

18 Years and older

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.